Drug repurposing against SARS-CoV-2: A review based on principal reports
Archivos Venezolanos de Farmacologia y Terapeutica
; 41(9):635-646, 2022.
Article
in English
| EMBASE | ID: covidwho-2239913
ABSTRACT
Despite the measures taken and the molecular advances for the development of new agents for the control of SARS-CoV-2 infection, there is still insufficient development of an effective treatment. The objective of the review was to de-scribe the clinical studies and reported articles on drugs used as possible therapeutic agents for COVID-19 and the main conclusions on their reuse. A non-systematic review through PubMed, ScienceDirect, and clinical trials at ClinicalTrials. gov on original articles and case report in English and Span-ish that will report information on COVID-19 treatment and its main conclusions. Articles that were not relevant or that did not mention updated information to that reported in other articles were excluded. A total of 99 bibliographic references were included. COVID-19 appears as a multisystemic disease with variable clinical symptoms. Since no specific treatment is yet known, multiple drugs have been proposed that attack the different pathways of SARS-CoV-2. For severe disease in patients who require hospitalization and oxygen support, the use of remdesivir, dexamethasone, or tocilizumab is recommended if there are patient conditions that apply to use them. The use of ivermectin, colchicine, lopinavir/ritonavir, hydroxy-chloroquine, and chloroquine have not reported benefits that surpass adverse effects.
alpha1b interferon; alpha2a interferon; alpha2b interferon; anakinra; azithromycin; bamlanivimab plus etesevimab; beta interferon; beta1b interferon; chloroquine; colchicine; dexamethasone; favipiravir; gamma interferon; hydroxychloroquine; interleukin 6 receptor; ivermectin; lambda interferon; lopinavir plus ritonavir; molnupiravir; nafamstat; nirmatrelvir plus ritonavir; nitazoxanide; nucleoside; peginterferon; proteinase inhibitor; remdesivir; ribavirin; sofosbuvir; sofosbuvir plus velpatasvir; sotrovimab; tocilizumab; umifenovir; antiretroviral therapy; antiviral activity; chill; computer assisted tomography; coronavirus disease 2019; cytotoxicity; depression; drug repositioning; EC50; erythema; fever; genotype; headache; hospital mortality; hospitalization; human; immune response; intensive care unit; JAK-STAT signaling; Medline; Middle East respiratory syndrome coronavirus; myalgia; oxygen therapy; phase 2 clinical trial (topic); randomized controlled trial (topic); review; SARS coronavirus; ScienceDirect; Severe acute respiratory syndrome coronavirus 2; skin necrosis; systematic review; virus load; virus replication; virus shedding
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Language:
English
Journal:
Archivos Venezolanos de Farmacologia y Terapeutica
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS